Clinical Trials
30 trialsCA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Washington University School of Medicine
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
CHANCES
Institut Paoli-Calmettes
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
H. Lee Moffitt Cancer Center and Research Institute
ROSETTE
Shanghai Zhongshan Hospital
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Dana-Farber Cancer Institute
Conversion Surgery After Target Therapy or Immunotherapy in Stage IV Gastric Cancer
Samsung Medical Center
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
China Medical University, China
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Qilu Hospital of Shandong University
FLOT5
Krankenhaus Nordwest
Miracle-G
Fudan University
Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC
The First Affiliated Hospital of Zhengzhou University
Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer
Memorial Sloan Kettering Cancer Center
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
Memorial Sloan Kettering Cancer Center
GASTHER2
AC Camargo Cancer Center
Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)
Yonsei University
Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer
Yonsei University
B-DOCT
The Netherlands Cancer Institute
FOLFIRINOX
Washington University School of Medicine
PETRARCA
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer
Memorial Sloan Kettering Cancer Center
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Memorial Sloan Kettering Cancer Center
PembroMab
Western Regional Medical Center
A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer
Peking University
Trastuzumab Based Therapy in HER2 Positive AGC
Shanghai Zhongshan Hospital
Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer
Sun Yat-sen University
A Study of Trastuzumab in Combination With TS-ONE & Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
National University Hospital, Singapore
NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer
National University Hospital, Singapore
Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric Cancer
Xuzhou Medical University
T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy
Chinese PLA General Hospital